Search For "drugs controller general of india dcgi"
Awaiting regulatory approval for rolling out Covaxin for children aged 2-1
Updated : 4 years, 9 months ago IST
New Delhi [India], October 12 (ANI): The Subject Expert Committee (SEC) has given a recommendation to the Drugs Controller General of India (DCGI) for the use of Bharat Biotech's COVID-19 vaccine, Covaxin, for the beneficiaries aged between 2-18 years, the official sources said on Tuesday
Read More
Approval to Covaxin for children aged between 2-18 years awaited after eva
Updated : 4 years, 9 months ago IST
New Delhi [India], October 12 (ANI): After the evaluation of data Covaxin is yet to get approval by the Drugs Controller General of India (DCGI) for children between 2-18 years old, according to official sources.
Read More
COVID-19: Subject Expert Committee gave recommendation to DCGI to use Cova
Updated : 4 years, 9 months ago IST
New Delhi [India], October 12 (ANI): Subject Expert Committee (SEC) has given a recommendation to the Drugs Controller General of India (DCGI) for the use of Bharat Biotech's COVID-19 vaccine Covaxin for the beneficiaries aged between 2-18 years, the official sources said.
Read More
Adolescents likely to get ZyCoV-D COVID vaccine after four weeks
Updated : 4 years, 10 months ago IST
New Delhi [India], August 23 (ANI): The Drugs Controller General of India (DCGI) on Friday approved Zydus Cadila's DNA vaccine for emergency use in adults and children aged 12 years and above.
Read More
India approves Zydus Cadila's ZyCoV-D vaccine for emergency use for adults
Updated : 4 years, 10 months ago IST
New Delhi [India], August 20 (ANI): Zydus Cadila's wait for a regulatory nod for its ZyCoV-D plasmid DNA vaccine against Covid is over. The Ahmedabad-based pharma company has received approval from the Drugs Controller General of India (DCGI).
Read More
Zydus Cadila submits additional data to DCGI for its COVID-19 vaccine: Sou
Updated : 4 years, 11 months ago IST
New Delhi [India], July 27 (ANI): Ahmedabad-based Zydus Cadila has submitted additional data related to immunogenicity and safety, on its three-dose COVID-19 vaccine ZyCoV-D, to India's drug regulator Drugs Controller General of India (DCGI), sources said on Tuesday.
Read More
Zydus Cadila expected to provide additional data on Covid-19 vaccine to DC
Updated : 4 years, 11 months ago IST
New Delhi [India], July 20 (ANI): Emergency approval for Zydus Cadila's Covid-19 vaccine may take a few more days with the Ahmedabad-based pharma company set to submit additional data related to immunogenicity and safety of its Zycov-D vaccine to the Drugs Controller General of India (DCGI)
Read More
DCGI examining Zydus Cadila's COVID vaccine for children, says Dr VK Paul
Updated : 4 years, 12 months ago IST
New Delhi [India], July 16 (ANI): Drugs Controller General of India (DCGI) is examining pharmaceutical major Zydus Cadila's COVID-19 vaccine for children, said Dr VK Paul, Member-Health, Niti Aayog on Friday.
Read More
Emergency approval for Zydus Cadila to take few more days, say sources
Updated : 5 years ago IST
New Delhi [India], July 12 (ANI): India's drug regulator Drugs Controller General of India (DCGI) will consider giving emergency use authorisation (EUA) to Zydus Cadila for its COVID-19 vaccine ZyCoV-D in a few more days, sources told ANI.
Read More
Zydus Cadila seeks emergency use authorisation for ZyCoV-D COVID-19 vaccin
Updated : 5 years ago IST
New Delhi [India], July 1 (ANI): Pharmaceutical major Zydus Cadila on Thursday applied for Emergency Use Authorisation (EUA) seeking approval from the Drugs Controller General of India (DCGI) for the launch of their ZyCoV-D vaccine for 12 years and above, sources said .
Read More
Johnson & Johnson won't be conducting COVID-19 vaccine trials in India
Updated : 5 years ago IST
New Delhi [India], June 29 (ANI): Johnson & Johnson will not be conducting local trials in India for its single-dose COVID-19 vaccine, a spokesperson of the US-based pharma company said on Tuesday.
Read More
DCGI likely to approve phase 3 trial data of Covaxin on Tuesday
Updated : 5 years ago IST
New Delhi [India], June 22 (ANI): The Drugs Controller General of India (DCGI) is likely to approve Phase III trial data of Covaxin on Tuesday, sources said.
Read More